Analysts Set Eli Lilly and Company (NYSE:LLY) Target Price at $938.61

Shares of Eli Lilly and Company (NYSE:LLY) have been assigned a consensus rating of “Moderate Buy” from the twenty-four analysts that are covering the firm, Marketbeat reports. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $936.4706.

A number of equities research analysts have issued reports on LLY shares. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Leerink Partners reissued a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th.

Insider Transactions at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its position in Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Wellington Management Group LLP lifted its position in Eli Lilly and Company by 0.6% during the 1st quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after acquiring an additional 81,587 shares during the period. Laurel Wealth Advisors LLC lifted its position in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Finally, Norges Bank purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $8,827,714,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock opened at $842.28 on Tuesday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm’s fifty day moving average is $777.69 and its 200 day moving average is $770.84. The firm has a market cap of $797.18 billion, a P/E ratio of 55.05, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.